BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

July 09, 2026 | News

Europe Approves TEPKINLY Combination as First Bispecific-Based Second-Line Therapy for Follicular Lymphoma

TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Euro...

July 08, 2026 | News

J-Pharma Advances First-in-Class LAT1 Inhibitor Nanvuranlat into Global Phase 3 Trial for Biliary Tract Cancer

Pharma Co., Ltd., a clinical-stage biotechnology company focused on novel therapies targeting amino acid transporters, and Uniphar, a leading international...

July 08, 2026 | News

Arima Genomics Partners with Active Motif to Expand Global Access to Hi-C Research Portfolio

Agreement Part of Arima’s Long-Term Strategy to Focus on Core Diagnostic Platform and Tests Arima Genomics, Inc., a cancer diagnostics com...

July 07, 2026 | News

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of saRNA Allergy Vaccine in Japan

First patient dosed less than one month after PMDA clearance, demonstrating rapid clinical execution Next-generation UNITE® saRNA-based immunother...

July 07, 2026 | News

Abu Dhabi DoH and MIT Koch Institute Partner to Advance AI-Enabled Oncology Research

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, and the MIT – Koch Institute for Integrative...

July 06, 2026 | News

Nona Biosciences and Lonza Partner to Develop Next-Generation BBB-Crossing Platform for CNS Therapies

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, announced ...

July 03, 2026 | News

Ribo and Madrigal Achieve First siRNA Candidate Milestone for MASH Therapy

Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with M...

July 03, 2026 | News

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR...

July 01, 2026 | News

Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?

A new medicine arrives at a regulator's desk with two kinds of proof attached. The first is the familiar kind: a randomised controlled trial, blinded, cont...

June 30, 2026 | Analysis

NS Pharma Parent Nippon Shinyaku Secures Global Option Rights to Develop Elixirgen's DMD Therapy EXG-7001

NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon S...

June 30, 2026 | News

AbbVie Secures U.S. FDA Approval for SKYRIZI in Children with Plaque Psoriasis and Psoriatic Arthritis

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or activ...

June 30, 2026 | News

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 for EGFR-Mutant Lung Cancer

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung ...

June 29, 2026 | News

Stay Connected